Allergan

Shareholders say in a federal class action that Allergan's stock dropped 41 percent in 15 months upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.

NEWARK, N.J. – Allergan shareholders say in a federal class action that drugmaker’s stock dropped 41 percent, from $319.47 in 2015 to $188.82 last month, upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.

Follow @bleonardcns

Categories / Business, Health, Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.